Life Biosciences Announces First Patient Dosed in Phase 1 Trial of ER‑100 for Optic Neuropathies (opens in new tab)

Lead epigenetic restoration therapy enters the clinic for glaucoma and NAION, targeting a root cause of age-related vision loss BOSTON, June 9, 2026 — Life Biosciences, Inc. (“Life Bio”), a biotechnology company pioneering cellular rejuvenation medicines to reverse diseases of aging, today announced that the first participant has been dosed in its Phase 1 clinical […]